copper(II) complex comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide binds copper through its histidine imidazole nitrogen, its terminal amino group, and a deprotonated amide nitrogen, creating a stable chelate ring. The resulting complex carries a distinctive blue to blue-violet color, which arises from copper d-d electronic transitions. In the solid state it is usually handled as a powder, while in solution the complex can dissociate and re-form depending on pH and competing ligands. The name copper tripeptide-1 is widely used in ingredient listings.
The tripeptide was first isolated from a human plasma filtrate in 1973 during studies of tissue repair factors. Later work detected the free peptide and its copper complex in saliva, urine, and wound fluid, suggesting a natural role in tissue remodeling. Plasma concentrations reported in early literature decline with age, a pattern often cited in discussions of skin aging. Whether these endogenous levels are directly functional or largely incidental remains an open question. The peptide sequence is conserved across mammalian species.
Research interest in GHK-Cu centers on its ability to deliver copper and to influence cellular processes in laboratory models. In cell culture and animal studies, the complex has been linked to collagen synthesis, antioxidant enzyme activity, and expression of genes associated with tissue remodeling. These effects are not equivalent to proven clinical outcomes. The mechanisms proposed include copper transfer to cuproenzymes, modulation of growth factor signaling, and interactions with extracellular matrix components. How much of the observed activity depends on intact GHK-Cu versus free copper or free peptide is not fully resolved.
The compound entered scientific literature in the 1970s, when plasma factors with copper-binding activity were isolated and characterized. Later work expanded into wound healing, skin biology, and cosmetic formulation, where copper tripeptide-1 became a recognized ingredient name. Most published studies remain preclinical or small-scale, and findings are often reported in specialized dermatology or peptide journals. Regulatory treatment varies: some jurisdictions allow it as a cosmetic ingredient, while research-grade material is sold for laboratory use. Questions about optimal delivery, target tissues, and long-term effects continue to be investigated rather than settled.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide sequence is often abbreviated Gly-His-Lys, and the copper is bound through the histidine imidazole nitrogen and adjacent peptide nitrogens. The complex is frequently described as a 1:1 peptide-to-copper species. It occurs naturally in human plasma, saliva, and urine at low concentrations. Its endogenous levels have been reported to decline with age, although the precise physiological role of that change remains an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C14H24N6O4 | Free tripeptide, without copper |
| Molecular weight | About 340 g/mol | Peptide portion only |
| Appearance | Blue to violet powder | Color from copper coordination |
| Solubility | Soluble in water | pH influences dissolution |
| Common synonyms | Copper tripeptide-1, Cu-GHK | Seen on ingredient labels |
GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine, a short sequence of three amino acids. The peptide was first isolated from human plasma in 1973 during research on factors that influence tissue repair in liver. Its ability to bind copper ions became a central point of interest because the metal changes the peptide's chemistry and its behaviour in laboratory systems. Today the compound appears in cosmetic formulations, cell-culture studies, and biochemistry literature under several names.
The peptide sequence places a histidine in the middle, and this residue dominates metal binding. Copper(II) coordinates through the imidazole nitrogen of histidine and the terminal amino group, forming a stable chelate ring system. Loss of the copper ion leaves the free tripeptide, which has different solubility and reactivity. This structural detail matters because assays that measure only the peptide backbone can miss whether copper is still bound to it.
Several names circulate for the same material, which complicates literature searches. Cosmetic ingredient lists often use copper tripeptide-1, while older biochemistry papers use glycyl-L-histidyl-lysine or its abbreviation GHK. The copper complex is sometimes written as GHK-Cu(II) to make the oxidation state explicit. Terminology is not fully standardized, so matching a compound across sources requires attention to the exact sequence, the counterion, and the stated copper content. Reviews that compare studies must account for these naming differences before drawing conclusions.
The peptide was first isolated from human albumin in 1973 by Loren Pickart, who later described its copper-binding behavior. Early work linked the complex to wound healing and tissue remodeling. Plasma levels of GHK decline with age, a pattern that stimulated interest in topical and supplemental applications. Researchers have reported that the tripeptide influences collagen synthesis, antioxidant defense, and inflammatory signaling in cell and animal models. Human clinical evidence remains limited and often relies on small studies.
Commercial products list GHK-Cu as copper tripeptide-1, a cosmetic ingredient. Formulators value its blue color and water solubility, which allow incorporation into serums, creams, and masks. Regulatory treatment varies: in the United States it appears in cosmetics, while some jurisdictions classify certain claims as drug-like. The compound is not an approved drug for any indication. Studies continue to examine its effects on skin, hair, and wound repair, but dosage, delivery, and long-term safety questions remain open.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and copper(II). The peptide sequence consists of glycine, histidine, and lysine, and its imidazole and amino groups provide binding sites for the metal ion. In the complex, copper is held through nitrogen donors from the histidine side chain, the N-terminal amine, and deprotonated amide nitrogens. The resulting compound is intensely blue and water-soluble. It occurs naturally in human plasma, saliva, and urine at low concentrations.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide backbone consists of glycine, histidine, and lysine joined in that order. Copper is held through the imidazole nitrogen of histidine and the alpha-amino group at the N-terminus, which together produce a square-planar arrangement around the metal center. The solid appears blue to violet, a color that originates from d-d electronic transitions within the copper coordination sphere. The complex is indexed under CAS number 89030-95-5.
The sequence now called GHK was first reported in the early 1970s after isolation from human plasma, where it was noted to influence liver cell behavior in laboratory preparations. Later work described a copper-binding form and its activity in fibroblast and wound-model experiments. Review articles frequently group the substance with other copper peptides. Concentrations in blood appear to fall with age in several small surveys, although the reason for this trend is not settled. Whether such a decline carries functional consequences remains an open question.
Published work on GHK-Cu concentrates largely on cell culture systems rather than whole organisms. Frequently used endpoints include collagen synthesis, expression of matrix metalloproteinases, and migration of fibroblasts. Some reports describe antioxidant behavior, while others stress delivery of copper into cells. These mechanisms are proposed rather than demonstrated, and the relative weight of each pathway is unclear. Human trials are few and generally small, so laboratory findings should not be read as confirmed clinical results.
GHK-Cu is the copper-binding complex formed by the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The free peptide is usually written as GHK, and the complex is written as GHK-Cu or Cu-GHK. The sequence was identified in human plasma and later detected in saliva and urine. Its name comes from the single-letter codes of glycine, histidine and lysine. The complex is widely described as a naturally occurring carrier of copper in blood rather than as a free peptide with its own hormonal role.
Copper binds to the peptide through the histidine imidazole nitrogen and the terminal amino group, forming a stable square-planar complex. Binding constants reported for copper(II) with GHK are high, so the peptide competes effectively for copper in solution. The complex absorbs visible light, which gives solutions a blue to violet colour. Whether the metal-free peptide has a distinct biological function of its own is still an open question; some work treats it mainly as a copper delivery vehicle, while other work reports peptide-specific effects.
The compound was first isolated from human plasma in the 1970s by Loren Pickart, who later described copper-binding activity in liver and other tissues. Early reports focused on its presence in blood and its ability to carry copper between proteins. Commercial and cosmetic use of the term 'copper peptide' has since broadened, and labels rarely distinguish GHK-Cu from other copper-binding fragments. This naming overlap makes literature searching harder, because cosmetic ingredient lists, supplier catalogues and laboratory papers use different vocabularies for the same molecule.
=== Seizures === Phenobarbital is used in the treatment of all types of seizures, except absence seizures. It is no less effective at seizure control than phenytoin, but phenobarbital is not as well tolerated. Phenobarbital may provide a clinical advantage over carbamazepine for treating partial seizures. Carbamazepine may provide a clinical advantage over phenobarbital for generalized tonic–clonic seizures. The first-line drugs for treatment of status epilepticus are benzodiazepines, such as lorazepam, clonazepam, midazolam, or diazepam. If these fail, then phenytoin may be used, with phenobarbital being an alternative in the US (favored in infants), but used only third-line in the UK. Failing that, the only treatment is anesthesia in intensive care. The World Health Organization (WHO) gives phenobarbital a first-line recommendation in the developing world and it is commonly used there. Phenobarbital is the first-line choice for the treatment of neonatal seizures. Concerns that neonatal seizures in themselves could be harmful make most physicians treat them aggressively. However, no reliable evidence supports this approach.
In the United States, 35% of babies born in 2018 were breastfed for 12 months, and 25.8% were exclusive breastfed for 6 months, as recommended by the American Academy of Pediatrics, though rates vary by race and ethnicity. In India, mothers commonly breastfeed for 2 to 3 years.
During a match against Borussia Mönchengladbach in 1996, Wenger presided over Rice's caretaker duties at Arsenal, and ordered the team to switch from their preferred 3–5–2 formation to 4–4–2. The tactical change did not have its desired effect, as Arsenal lost the game having led before Wenger's half-time instruction. For much of the 1996–97 season, Arsenal continued to play 3–5–2 as it was the only formation the defenders were comfortable with, as well as injuries unsettling the side. In Wenger's second season at the club, he reinstated 4–4–2 and focused on strengthening the front six, by signing wingers Overmars and Luís Boa Morte and partnering Vieira with Petit. According to Jonathan Wilson, the system was similar to 4–3–3, as Overmars often pushed higher up the field and Parlour played alongside Vieira and Petit to solidify the midfield. Needing to compensate deficiencies in attack the following season, Wenger relied on his experienced defence to direct games, which conceded 17 goals in 38 league matches. From then on, Wenger deployed an unconventional 4–4–2 with a greater emphasis on attack and movement; his teams between 2001 and 2004 were dominant on the left flank. By the 2005–06 season, clubs in England were increasingly in favour of using the 4–5–1 system. Wenger, having earlier suggested he would never resort to a negative system, later adopted the formation for Champions League matches. The decision to pack the midfield and play a lone striker resulted in Arsenal reaching the final.
The new 10th district stretches from downtown and western Austin (including Lake Travis) through the Bryan–College Station area to a rural stretch of east-central Texas between Houston, Dallas and Tyler, including Crockett, Livingston and Madisonville. The district was redrawn during Texas's 2025 mid-decade congressional redistricting. Chris Gober, who subsequently became the Republican nominee for the district, had participated professionally in Republican congressional redistricting efforts. During the 2021 Texas redistricting process, 22 Republican members of the Texas Legislature retained Gober, who in turn retained the National Republican Redistricting Trust and obtained the services of Republican mapmaker Adam Kincaid. According to Gober's deposition, Kincaid operated the map-drawing software used for the congressional maps. He subsequently redrew the 10th Congressional district to include his own residence and those of his client, Elon Musk, as well as the land Musk had already identified for his Terafab Project. Through his co-founded nationwide law firm Lex Politica (formerly known as The Gober Group) Gober has represented numerous elected Republican officials in federal ethics investigations. Since 2024, he has served as the director and chief lawyer of entrepreneur Elon Musk's America PAC, including in support of then-nominee Donald Trump's presidential campaign. He defended the PAC against several lawsuits filed by state and city governments regarding its $1 million lottery for voters in swing states.
Sources: en.wikipedia.org
==== Canada, United Kingdom, and Europe ==== In Canada, e-cigarettes had an estimated value of 140 million CAD in 2015. There are numerous e-cigarette retail shops in Canada. A 2014 audit of retailers in four Canadian cities found that 94% of grocery stores, convenience stores, and tobacconist shops which sold e-cigarettes sold nicotine-free varieties only, while all vape shops stocked at least one nicotine-containing product. By 2015, the e-cigarette market had only reached a twentieth of the size of the tobacco market in the UK. In the UK in 2015 the "most prominent brands of cigalikes" were owned by tobacco companies, however, with the exception of one model, all the tank types came from "non-tobacco industry companies". Yet some tobacco industry products, while using prefilled cartridges, resemble tank models. By 2023, 1 survey by the Local Data Company counted 3,573 specialist vape shops in the UK, and NIQ data cited in press reporting put value sales of vaping products in Britain at £897.4 million. Sky News similarly reported that more than 230 independent vape shops opened in 2023, citing the same Local Data Company survey. France's e-cigarette market was estimated by Groupe Xerfi to be €130 million in 2015. Additionally, France's e-liquid market was estimated at €265 million. In December 2015, there were 2,400 vape shops in France, 400 fewer than in March of the same year. Industry organization Fivape said the reduction was due to consolidation, not to reduced demand.
Drug Delivery: Developing Countries The drug delivery mechanisms have the potential to enhance the health of all parts of the world despite the fact that most of the advanced systems are quite costly to the poor nations. Simple system, orals or skin patch, is more feasible in low resource countries. Most countries have used vaccines that are administered orally to combat such diseases as polio (Yenet et al., 2023). The government and the hospital organizations need to collaborate in order to reduce the cost and offer the new means of drug distribution that will allow giving the new medications everywhere. Ethical and Safety Issues Emerging drug delivery devices such as nanoparticles or gene therapies are highly dangerous in terms of safety and equity. For example, we should make sure that the treatments would not negatively affect the environment or cause any incidental side effects. The regulation of other agencies such as FDA are applied in the process of ensuring the safety of new practices but vary across countries (World Health Organization, 2024). The government has the mandate of making sure that medicine is not only affordable to the wealthy members of the society, but also to the vulnerable ones as well. The issue of drug delivery has raised a number of ethical concerns with respect to patients and healthcare systems. One common concern is the accessibility of specific medications within a health organization.
=== Shutdown === On September 4, 2018, Theranos announced in an email to investors that it would cease operations and release its assets and remaining cash to creditors after all efforts to find a buyer were fruitless. Most of the company's remaining employees had been laid off on the previous Friday, August 31. However, Theranos general counsel and new CEO David Taylor and a few support staffers remained on payroll for a few more days. Any equity investments in the company were made worthless by the shutdown. Theranos would later transfer its patents to Fortress Investment Group on September 12 in exchange for Theranos's cash assets to be distributed to creditors.
Sources: en.wikipedia.org
=== Health experiences === Trans people report multiple negative experiences in health care encounters, contributing to stigmatization of their gender identity. A systematic review conducted by researchers at James Cook University reported that 75.3% of respondents have negative experiences during physician visits when seeking gender identity-based care. Transgender patients also face obstacles to accessing health care that result in adverse effects on their health and quality of life. These include unsafe public spaces, lack of knowledgeable health care professionals, discrimination while accessing care, lack of institutional support, long distances to access treatment, and denial of health care services and health insurance benefits. These often result in trans people avoiding or delaying health care. Trans patients may also avoid treatment as a result of their gender identities being treated as psychological illnesses, or because they fear "discrimination and suboptimal or inappropriate care" as a result of disclosing their gender identities. For instance, after a transgender man seeking medical care in the emergency department was verbally assaulted by the hospital employees, who repeatedly referred to him as a woman, he left the hospital premises before receiving the care he needed. According to a systematic review conducted by Hermaszewska and colleagues, "some transgender people are forced to migrate to countries that offer them better legal protection and wider social acceptance". Others may self-prescribe medication such as gender-affirming hormone therapy.
The white shark is the sole living species in the genus Carcharodon and is one of five living species of the family Lamnidae. The other four members of this family are the mako sharks, porbeagle, and salmon shark. The family belongs to the Lamniformes, the order of mackerel sharks. The white shark first appears in the fossil record in the Pacific basin around 6–5 mya, between the late Miocene and early Pliocene. Like all sharks, the white shark's skeleton is made primarily of soft cartilage that does not preserve well. As a result, the overwhelming majority of fossils are teeth. Nevertheless, paleontologists have traced the emergence of the white shark and its immediate ancestry to a large extinct shark known as Carcharodon hastalis. This species had teeth similar to the modern white shark's, except for the cutting edges, which lacked serrations. C. hastalis occupied a similar position in the food web to modern white sharks and was probably mostly fish-eating, with some marine mammals in its diet, though its lack of serrations made it a less efficient predator of them. Around 8–6 mya, a Pacific population of C. hastalis evolved into C. hubbelli. This divergent lineage was characterized by a gradual development of serrations over the next few million years. Teeth from the same time period may exhibit significant variation in shape and their serrations, which may be indicative of persistent interbreeding with C. hastalis for at least some time. White sharks descended from C.
The Crossbell arc consists of two games. They are set in Crossbell, a city-state located between the great powers of Erebonia and Calvard. It follows rookie police investigator Lloyd Bannings and the Special Support Section, consisting of himself, Elie McDowell, Randy Orlando, and Tio Plato, as they protect the city from criminal activity and the geopolitical situation that looms over it. The first game, Trails from Zero, was released in Japan for the PSP in 2010. The second, Trails to Azure, was released in Japan for the PSP in 2011. The duology did not see official English release for over a decade until NIS America took over rights to the series' English localization in 2019. They released Trails from Zero in 2022 and Trails to Azure in 2023 for PlayStation 4, Nintendo Switch, and Windows. Unlike other English language releases in the Trails series, the Crossbell arc lacks English audio and only includes English subtitles with Japanese audio.
=== Essays === FEMEN, Manifeste FEMEN, éditions Utopia, 2014 ISBN 978-2919160174. Héroïnes de la rue, Manifeste pour un féminisme de combat, éditions Michel Lafon, 2020 ISBN 978-2749943961. avec Dora Moutot, Transmania, Magnus, 2024.
Sources: en.wikipedia.org
It is a complex of the tripeptide glycyl-L-histidyl-L-lysine with a copper(II) ion. The peptide coordinates the metal through its histidine, amino terminus, and an amide nitrogen. It is often listed simply as copper tripeptide-1.
The peptide and its copper form have been detected in human plasma, saliva, and urine. Early reports describe levels that fall with age. The functional meaning of these pools is still debated.
Chromatographic separation gives peptide purity, often reported as a percentage. Copper content is checked by a separate elemental method. Moisture and counter-ions may be reported as well.
GHK-Cu is a complex of the tripeptide glycyl-L-histidyl-L-lysine with copper(II). The peptide binds copper through its histidine residue and neighboring amide nitrogens, forming a stable coordination compound. It is studied as a research chemical and used in some cosmetic formulations.